The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Evaluating CDK4/6 and cyclin D1 as biomarkers in GEA treatment
Ronan Joseph Kelly, MD, Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas, TX, comments on a Phase I/II study (NCT04921904) of abemaciclib and ramucirumab in pretreated metastatic gastroesophageal adenocarcinoma (GEA). The regimen was generally well tolerated and showed modest clinical activity in the second- and third-line settings. Patients with CDK4/6 or cyclin D1 pathway alterations appeared to derive greater benefit, suggesting a potential biomarker for treatment selection. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
